Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd VYYRF


Primary Symbol: V.VM

Healthcare Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Voyageur Pharmaceuticals Ltd > New Press Release - Voyageur Achieves Milestone with Rain Cage Royalty Agreement for Sustainable Carbon Drug Development
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(58)
•••
Comment by WarrantOfficeron Mar 13, 2024 3:55pm
107 Views
Post# 35931243

RE:RE:RE:New Press Release - Voyageur Achieves Milestone with Rain Cage Royalty Agreement for Sustainable Carbon Drug Development

RE:RE:RE:New Press Release - Voyageur Achieves Milestone with Rain Cage Royalty Agreement for Sustainable Carbon Drug DevelopmentI agree whitenorth72. The pharma field is frightening competitive. Releasing details of Royalty Agreements could turn catastrophic. Competitiors always ready to pounce. Patiently waiting for release of barium sulphate product line in the next couple of months. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities